Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cancer Med ; 7(6): 2718-2726, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29733510

RESUMO

Although multigene panel testing is increasingly common in patients with cancer, the relationship between its use among breast cancer patients with non-BRCA mutations or variants of uncertain significance (VUS) and disease management decisions has not been well described. This study evaluated the rate and predictive factors of CPM patients who underwent multigene panel testing. Three hundred and fourteen patients with breast cancer who underwent multigene panel testing between 2014 and 2017 were included in the analysis. Of the 314 patients, 70 elected CPM. Election of CPM by gene status was as follows: BRCA carriers (42.3%), non-BRCA carriers (30.1%), and VUS (10.6%). CPM election rates did not differ between non-BRCA carriers and BRCA carriers (P = 0.6205). Among non-BRCA carriers, negative hormone receptor status was associated with CPM (P = 0.0115). For those with a VUS, hormone receptor status was not associated with CPM (P = 0.1879). Although the rate of CPM between BRCA carriers and non-BRCA carriers was not significantly different, the predictors of CPM were different in each group. Our analyses shed the light on the increasing use of CPM among patients who are non-BRCA carriers as well those with a VUS. Our study elucidates the differing predictive factors of CPM election among BRCA carriers, non-BRCA carries, and those with a VUS. Our findings reveal the need for providers to be cognizant that non-BRCA genes and VUS drive women to elect CPM despite the lack of data for contralateral breast cancer risk associated with these genes.


Assuntos
Biomarcadores Tumorais , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/genética , Neoplasias Unilaterais da Mama/epidemiologia , Neoplasias Unilaterais da Mama/prevenção & controle , Adulto , Idoso , Proteína BRCA1/genética , Proteína BRCA2/genética , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/cirurgia , Feminino , Testes Genéticos , Genótipo , Humanos , Incidência , Pessoa de Meia-Idade , Prognóstico , Mastectomia Profilática , Modelos de Riscos Proporcionais , Neoplasias Unilaterais da Mama/etiologia , Neoplasias Unilaterais da Mama/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...